FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ingemar Turesson

Research Profile

Disorders

Procedures

Chemicals & Drugs

Geographic Areas

Sweden

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sigurdur Y Kristinsson; Ola Landgren; Ingemar Turesson; Therese M-L Andersson; Paul W Dickman; Sandra Eloranta; Magnus Björkholm
Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
Sigurdur Y Kristinsson; Magnus Björkholm; Cecilie Blimark; Lynn R Goldin; Ulf-Henrik Mellqvist; Ruth M Pfeiffer; Min Tang; Ingemar Turesson; Anders Wahlin; Ola Landgren
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.
Anish Thomas; Ingemar Turesson; Neha Korde; Sigurdur Y Kristinsson; Sham Mailankody; Ola Landgren
Second malignancies after multiple myeloma: from 1960s to 2010s.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ingemar Turesson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sigurdur Y Kristinsson; Ola Landgren; Ingemar Turesson; Therese M-L Andersson; Paul W Dickman; Sandra Eloranta; Magnus Björkholm
Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
American journal of hematology 2013;88(1):60-5.
2012: Sigurdur Y Kristinsson; Magnus Björkholm; Cecilie Blimark; Lynn R Goldin; Ulf-Henrik Mellqvist; Ruth M Pfeiffer; Min Tang; Ingemar Turesson; Anders Wahlin; Ola Landgren
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.
Haematologica 2012;97(6):854-8.
2012: Anish Thomas; Ingemar Turesson; Neha Korde; Sigurdur Y Kristinsson; Sham Mailankody; Ola Landgren
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood 2012;119(12):2731-7.
2012: Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.
Acta haematologica 2012;127(3):173-7.
2011: Sham Mailankody; Ruth M Pfeiffer; Ingemar Turesson; Magnus Bjorkholm; Lynn R Goldin; Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
Blood 2011;118(15):4086-92.
2011: Sigurdur Yngvi Kristinsson; Ingemar Turesson
The association of cancer and venous thrombosis: yes, Trousseau is right...again!
Leukemia & lymphoma 2011;52(5):734-5.
2010: Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.
Blood 2010;116(15):2651-5.
2010: Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.
Blood 2010;115(24):4991-8.
2010: Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.
Mayo Clinic proceedings. Mayo Clinic 2010;85(3):225-30.
2010: Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):830-4.
2009: Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.
Haematologica 2009;94(12):1714-20.
2009: Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
Haematologica 2009;94(11):1581-9.
2009: Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.
International journal of cancer. Journal international du cancer 2009;125(9):2147-50.
2009: Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.
Blood 2009;114(4):791-5.
2009: Sigurdur Y Kristinsson; Jill Koshiol; Lynn R Goldin; Magnus Björkholm; Ingemar Turesson; Gloria Gridley; Mary L McMaster; Ola Landgren
Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia.
Clinical lymphoma & myeloma 2009;9(1):23-6.
2008: Sigurdur Y Kristinsson; Thomas R Fears; Gloria Gridley; Ingemar Turesson; Ulf-Henrik Mellqvist; Magnus Björkholm; Ola Landgren
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.
Blood 2008;112(9):3582-6.
2006: Ulla Olsson-Strömberg; Mattias Höglund; Magnus Björkholm; Inger Braide; Kristina Carlson; Gösta Gahrton; Gunnar Grimfors; Robert Hast; Rickard Lerner; Olle Linder; Per Ljungman; Eva Löfvenberg; Claes Malm; Per-Gunnar Nilsson; Christer Paul; Stig Rödjer; Leif Stenke; Ulf Tidefeldt; Ingemar Turesson; Ann-Marie Uden; Ake Wahlin; Lars Vilen; Ingemar Winqvist; Olle Zettervall; Gunnar Oberg; Bengt Simonsson
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Leukemia & lymphoma 2006;47(9):1768-73.
2006: Stig Lenhoff; Martin Hjorth; Ingemar Turesson; Jan Westin; Peter Gimsing; Finn Wislöff; Lucia Ahlberg; Kristina Carlson; Ilse Christiansen; Inger Marie S Dahl; Karin Forsberg; Lorentz Brinch; Jens Hammerström; Hans E Johnsen; Lene Meldgaard Knudsen; Olle Linder; Ulf-Henrik Mellqvist; Ingerid Nesthus; Johan Lanng Nielsen
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
Haematologica 2006;91(9):1228-33.
2006: Stig Lenhoff; Martin Hjorth; Jan Westin; Lorentz Brinch; Bengt Bäckström; Kristina Carlson; Ilse Christiansen; Inger Marie S Dahl; Peter Gimsing; Jens Hammerström; Hans E Johnsen; Gunnar Juliusson; Olle Linder; Ulf-Henrik Mellqvist; Ingerid Nesthus; Johan Lanng Nielsen; Jon Magnus Tangen; Ingemar Turesson
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
British journal of haematology 2006;133(4):389-96.
2005: Philip R Greipp; Jesús San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Hervé Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan José Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
International staging system for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3412-20.
2005: Bengt Simonsson; Gunnar Oberg; Mats Bjoreman; Magnus Bjorkholm; Jan Carneskog; Karin Karlsson; Gösta Gahrton; Gunnar Grimfors; Robert Hast; Hans Karle; Olle Linder; Per Ljungman; Johan Lanng Nielsen; Jonas Nilsson; Eva Lofvenberg; Claes Malm; Karin Olsson; Ulla Olsson-Stromberg; Christer Paul; Leif Stenke; Jesper Stentoft; Ingemar Turesson; Ann-Mari Udén; Ake Wahlin; Lars Vilén; Ole Weis-Bjerrum
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Acta haematologica 2005;113(3):155-62.
2004: Therese Nilsson; Lars Nilsson; Stig Lenhoff; Lars Rylander; Ingbritt Astrand-Grundström; Bodil Strömbeck; Mattias Höglund; Ingemar Turesson; Jan Westin; Felix Mitelman; Sten E W Jacobsen; Bertil Johansson
MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
Genes, chromosomes & cancer 2004;41(3):223-31.
2004: Therese Nilsson; Stig Lenhoff; Lars Rylander; Mattias Höglund; Ingemar Turesson; Felix Mitelman; Jan Westin; Bertil Johansson
High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
British journal of haematology 2004;126(4):487-94.
2004: Anne-Tove Brenne; Lene Hejna Romstad; Peter Gimsing; Gunnar Juliusson; Ingemar Turesson; Pål Romundstad; Magne Borset; Anders Sundan; Anders Waage
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Haematologica 2004;89(5):552-6.
2004: Anders Waage; Peter Gimsing; Gunnar Juliusson; Ingemar Turesson; Nina Gulbrandsen; Tommy Eriksson; Martin Hjorth; Johan Lanng Nielsen; Stig Lenhoff; Jan Westin; Finn Wislöff
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.
British journal of haematology 2004;125(2):149-55.
2004: Ulla Olsson-Strömberg; Bengt Simonsson; Tomas Ahlgren; Magnus Björkholm; Karin Carlsson; Gösta Gahrton; Robert Hast; Eva Löfvenberg; Olle Linder; Per Ljungman; Claes Malm; Christer Paul; Stig Rödjer; Ingemar Turesson; Ann-Mari Udén; Ake Wahlin; Andreas Killander; Bengt Wadman; Jan Westin; Olle Vikrot; Olle Zettervall; Gunnar Oberg
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(6):462-6.
2003: Tommy Eriksson; Peter Höglund; Ingemar Turesson; A Waage; Burl R Don; J Vu; M Scheffler; George A Kaysen
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
The Journal of pharmacy and pharmacology 2003;55(12):1701-6.
2003: Robert Hast; Eva Hellström-Lindberg; L Ohm; Magnus Björkholm; Fredrik Celsing; Inger Marie S Dahl; Ingunn Dybedal; Gösta Gahrton; G Lindberg; Richard Lerner; Olle Linder; Eva Löfvenberg; H Nilsson-Ehle; Christer Paul; Jan Samuelsson; Jon Magnus Tangen; Ulf Tidefelt; Ingemar Turesson; Ake Wahlin; Jonas Wallvik; Ingemar Winquist; Gunnar Oberg; Per Bernell
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Leukemia 2003;17(9):1827-33.
2003: Aikaterini Barbouti; Tomas Ahlgren; Bertil Johansson; Mattias Höglund; Carin Lassen; Ingemar Turesson; Felix Mitelman; Thoas Fioretos
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
British journal of haematology 2003;122(1):85-93.
2003: Thérèse Nilsson; Mattias Höglund; Stig Lenhoff; Lars Rylander; Ingemar Turesson; Jan Westin; Felix Mitelman; Bertil Johansson
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.
British journal of haematology 2003;120(6):960-9.
2002: Carina Seidel; Stig Lenhoff; Sigmund Brabrand; Gøran Anderson; Therese Standal; Johan Lanng-Nielsen; Ingemar Turesson; Magne Børset; Anders Waage
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.
British journal of haematology 2002;119(3):672-6.
2002: Ulla Axdorph; Leif Stenke; Gunnar Grimfors; Jan Carneskog; Jan Hansen; Olle Linder; Per Ljungman; Eva Löfvenberg; Claes Malm; Bengt Simonsson; Ingemar Turesson; Lars Vilén; Ann-Mari Udén; Magnus Björkholm
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
British journal of haematology 2002;118(4):1048-54.
2002: Helene Hallböök; Bengt Simonsson; Tomas Ahlgren; Magnus Björkholm; Jan Carneskog; Gunnar Grimfors; Robert Hast; Karin Karlsson; Eva Kimby; Richard Lerner; Olle Linder; Mats Linderholm; Eva Löfvenberg; Claes Malm; Per-Gunnar Nilsson; Christer Paul; Leif Stenke; Dick Stockelberg; Ulf Tidefelt; Ingemar Turesson; Ann-Marie Uden-Blome; Lars Vilen; Ake Wahlin; Ingemar Winquist; Bengt Smedmyr
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
British journal of haematology 2002;118(3):748-54.
2002: T Nilsson; Stig Lenhoff; Ingemar Turesson; Lars Rylander; Felix Mitelman; Jan Westin; Mattias Höglund; Bertil Johansson
Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation.
European journal of haematology 2002;68(6):345-53.
2001: Nina Gulbrandsen; Finn Wisløff; Lorentz Brinch; Kristina Carlson; Inger Marie S Dahl; Peter Gimsing; Erik Hippe; Martin Hjorth; Lene Meldgaard Knudsen; J Lamvik; Stig Lenhoff; E Løfvenberg; Ingerid Nesthus; Johan Lanng Nielsen; Ingemar Turesson; Jan Westin
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
Medical oncology (Northwood, London, England) 2001;18(1):65-77.
2000: Martin Hjorth; Stig Lenhoff; Ingemar Turesson; Jan Westin
[High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].
Läkartidningen 2000;97(41):4585-6, 4589-92.
2000: Gunnar Juliusson; Fredrik Celsing; Ingemar Turesson; Stig Lenhoff; M Adriansson; Claes Malm
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.
British journal of haematology 2000;109(1):89-96.
2000: Carina Seidel; Anders Sundan; Martin Hjorth; Ingemar Turesson; Inger Marie S Dahl; Niels Abildgaard; Anders Waage; Magne Borset
Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
Blood 2000;95(2):388-92.
2000: Stig Lenhoff; Martin Hjorth; Erik Holmberg; Ingemar Turesson; Jan Westin; Johan Lanng Nielsen; Finn Wislöff; Lorentz Brinch; Kristina Carlson; M Carlsson; Inger Marie S Dahl; Peter Gimsing; Erik Hippe; H E Johnsen; H Johnsen; J Lamvik; Eva Löfvenberg; Ingerid Nesthus; Stig Rödjer
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
Blood 2000;95(1):7-11.
1999: Ingemar Turesson; Niels Abildgaard; Tomas Ahlgren; Inger Marie S Dahl; Erik Holmberg; Martin Hjorth; Johan Lanng Nielsen; A Odén; Carina Seidel; Anders Waage; Jan Westin; Finn Wislöff
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
British journal of haematology 1999;106(4):1005-12.
1999: Inger Marie S Dahl; Ingemar Turesson; Erik Holmberg; K Lilja
Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration.
Blood 1999;93(12):4144-8.
1999: Kristina Carlson; A Larsson; Bengt Simonsson; Ingemar Turesson; Jan Westin; Sverker Ljunghall
Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
European journal of haematology 1999;62(5):300-6.
1999: Martin Hjorth; E Holmberg; Stig Rödjer; Ingemar Turesson; Jan Westin; Finn Wislöff
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG).
European journal of haematology 1999;62(4):271-7.
1998: H Brincker; Jan Westin; Niels Abildgaard; Peter Gimsing; Ingemar Turesson; M Hedenus; J Ford; A Kandra
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
British journal of haematology 1998;101(2):280-6.
1998: Carina Seidel; Magne Børset; Ingemar Turesson; Niels Abildgaard; Anders Sundan; Anders Waage
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.
Blood 1998;91(3):806-12.
1996: Bengt Simonsson; Gunnar Oberg; M Björeman; Magnus Björkholm; Jan Carneskog; Gösta Gahrton; Robert Hast; H Karl; J Lanng-Nielsen; E Löfvenberg; Claes Malm; Ingemar Turesson; A M Udén; L Vilén; O Weis-Bjerrum
Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
Bone marrow transplantation 1996;17 Suppl 3():S63-4.
1995: Jan Westin; Stig Rödjer; Ingemar Turesson; A Cortelezzi; Martin Hjorth; G Zador
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
British journal of haematology 1995;89(3):561-8.
1994: Bengt Simonsson; Gunnar Oberg; A Killander; M Björeman; Magnus Björkholm; Gösta Gahrton; Leif Stenke; Ingemar Turesson; A M Udén; Claes Malm
Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Swedish CML-group.
Bone marrow transplantation 1994;14 Suppl 3():S55-6.
1993: Bengt Simonsson; Gunnar Oberg; A Killander; M Björeman; M Börkholm; Gösta Gahrton; Robert Hast; Ingemar Turesson; A M Udén; Claes Malm
Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():73-6.
1993: Thoas Fioretos; Per-Gunnar Nilsson; Pierre Aman; Sverre Heim; Ulf Kristoffersson; Claes Malm; Bengt Simonsson; Ingemar Turesson; Felix Mitelman
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.
Leukemia 1993;7(8):1225-31.
1992: Finn Wisløff; Peter Gimsing; M Hedenus; E Hippe; I Palva; I Talstad; Ingemar Turesson; Jan Westin
Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG).
European journal of haematology 1992;48(2):70-4.
1992: Bengt Simonsson; Gunnar Oberg; M Björeman; Magnus Björkholm; Gösta Gahrton; Robert Hast; A Killander; Ingemar Turesson; A M Udén; O Vikrot
Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia.
Leukemia & lymphoma 1992;7 Suppl():55-7.
1991: Jan Westin; A Cortelezzi; Martin Hjorth; Stig Rödjer; Ingemar Turesson; G Zador
Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 4():S45-8.
1990: Fredrik Mertens; Bertil Johansson; Sverre Heim; Ulf Kristoffersson; Nils Mandahl; Ingemar Turesson; Claes Malm; A Othzén; C R Bartram; D Catovsky
Trisomy 14 in atypical chronic myeloid leukemia.
Leukemia 1990;4(2):117-20.